Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have one of these cancers that can't be removed by surgery or has spread: pancreatic, non-small cell lung, breast (HR+/HER2- or triple-negative), or colorectal.
- Your cancer must have gotten worse after at least one standard treatment (or you cannot have those treatments).
- A special scan must show that a tracer (68Ga-NNS309) sticks to your tumors.
- You must not have serious kidney, heart, or blood problems, and you cannot have had radiation therapy in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
This trial tests a radioactive imaging agent that may help doctors see tumors more clearly using a special scan. It is designed for adults with certain breast, lung, or stomach cancers that have spread.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
This trial tests a new radioactive drug (called 177Lu-DWJ155) that targets and kills cancer cells, along with a similar imaging agent (68Ga-DWJ155) used to see where the drug goes in the body. It is for people with certain advanced solid tumors that have not responded to standard therapies.
This trial tests a new targeted radioactive drug that seeks out a specific marker on lung cancer cells. It first uses a low-dose imaging scan to see if the cancer cells have this marker, then gives a higher-dose treatment to destroy those cells.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.